Sio Gene Therapies Inc.
SIOX · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $0 | $6 | $13 |
| G&A Expenses | $3 | $3 | $3 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $3 | $9 | $13 |
| Operating Income | -$5 | -$3 | -$9 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$3 | -$8 | -$13 |
| Tax Expense | -$1 | -$0 | -$0 | $0 |
| Net Income | -$3 | -$3 | -$8 | -$13 |
| % Margin | – | – | – | – |
| EPS | -0.046 | -0.041 | -0.11 | -0.18 |
| % Growth | -13.2% | 62.9% | 38.9% | – |
| EPS Diluted | -0.046 | -0.041 | -0.11 | -0.18 |
| Weighted Avg Shares Out | 74 | 74 | 74 | 74 |
| Weighted Avg Shares Out Dil | 74 | 74 | 74 | 74 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | -$13 |
| % Margin | – | – | – | – |